KPV peptide is the anti-inflammatory tripeptide of alpha-MSH, studied across gut, colitis, and epithelial-repair research.

In plain English

KPV peptide is a tiny molecule made of three amino acids — lysine, proline, and valine — clipped from the tail end of a natural body hormone called alpha-MSH. The interesting part: it seems to keep the calming, anti-inflammatory side of that hormone while dropping the part that darkens skin. Almost all of what we know comes from cells in a dish and from mice, especially studies of inflamed bowels. There are no human clinical trials. This site lays out what those studies actually measured, and, on the other side of the page, where legal access honestly stands.

KPV at a glance: the C-terminal tripeptide of alpha-MSH

KPV is a linear tripeptide — lysine-proline-valine, written H-Lys-Pro-Val-OH — with the molecular formula C16H30N4O4 and a molecular weight of about 342.44 Da ^[1]. It corresponds to residues 11-13, the C-terminal sequence, of alpha-melanocyte-stimulating hormone (alpha-MSH, a small signaling hormone the body makes that has both anti-inflammatory and skin-pigmenting actions) ^[4]. KPV is not an independently circulating hormone; it is the fragment at the hormone's tail.

What makes that fragment worth a research literature is a clean split of function. Full alpha-MSH does two broad things — it calms inflammation and it drives pigment. KPV retains the anti-inflammatory activity while lacking the pigmentary (melanogenic) action of the whole hormone ^[4]. Across cell and animal models it dampens inflammatory signaling, and in the gut it is carried directly into the cells lining the intestine by a small-peptide transporter called PepT1 ^[1].

The research that follows is preclinical. KPV is a research compound: it is not approved by the FDA for any human use, and there are no published human clinical trials ^[1][2]. Everything quantitative on this site comes from cell studies and animal models, and is cited as such.

What the published research has demonstrated

The strongest body of KPV work is in the gut. Nanomolar KPV — concentrations around 10 nM — reduced NF-kB (a master switch that turns on inflammatory genes) and MAP-kinase activation and lowered pro-inflammatory cytokine output in human intestinal epithelial cells and Jurkat T cells; in mice, oral KPV given at about 100 uM in drinking water reduced the severity of both DSS- and TNBS-induced colitis ^[1]. A second team reported that KPV-treated mice in a DSS colitis model recovered earlier and regained body weight more strongly, with less colonic inflammatory infiltrate and lower myeloperoxidase activity — and the effect held up in MC1R-deficient mice, pointing to a melanocortin-receptor-independent mechanism ^[2].

The peptide's reach extends past the gut. Topical KPV accelerated corneal epithelial wound healing in rabbits: by 60 hours, all eight corneas treated with KPV were completely re-epithelialized, versus none of the placebo-treated corneas ^[6]. And in macrophages and a peritonitis model, KPV reduced leukocyte accumulation through an action distinct from the core MSH peptides, with evidence pointing to inhibition of IL-1beta function rather than receptor agonism ^[3].

For the full KPV anti-inflammatory mechanism — how KPV reduces inflammation via NF-kB and MAPK and PepT1-mediated uptake of KPV — see the dedicated mechanism page. For KPV colitis and IBD research, the gut section on the research page goes deeper, and KPV dosing in the research literature collects the concentrations and routes the studies used. Where access actually stands is covered under KPV legal status and FDA 503A category. Every figure here is logged in references and citations. These are study findings in cells and animals, not established human outcomes.

Definitions, structure, and what KPV is for

This site keeps four common reader questions answered up front, in plain language, before the deeper pages.